Dr. Campbell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
MD Anderson Cancer Center, Department of GU Medical Oncology
1155 Pressler St, CPB 7.3450, Unit 1374
Houston, TX 77030Phone+1 713-792-2121Fax+1 713-745-0422- Is this information wrong?
Education & Training
- University of Texas Graduate School of Biomedical SciencesMasters in Science, Biomedical Research and Translational Research, 2013 - 2015
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- Indiana University School of MedicineChief Residency, Internal Medicine, 2011 - 2012
- Indiana University School of MedicineResidency, Internal Medicine, 2008 - 2011
- Indiana University School of MedicineClass of 2007
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2013 - 2025
- TX State Medical License 2019 - 2025
- OK State Medical License 2020 - 2021
- IN State Medical License 2010 - 2013
Awards, Honors, & Recognition
- Teacher of the Year Award MD Anderson Cancer Center Hematology/Medical Oncology Fellowship, 2018
- Humanitas Award for Excellent Patient Care UT MD Anderson Cancer Center, 2015
- Chief Fellow Hematology/Medical Oncology Fellowship MD Anderson Cancer Center, 2014-2015
- Join now to see all
Clinical Trials
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Start of enrollment: 2017 Dec 28
- Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer Start of enrollment: 2018 May 29
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Start of enrollment: 2018 May 15
- Join now to see all
Publications & Presentations
PubMed
- Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.Rhenita Amirtharaj, Lianchun Xiao, Dzifa Y Duose, Shufang Wang, Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Suzanne Lange, Suma...> ;The Journal of Urology. 2024 Apr 10
- Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.Andrew C Johns, Matthew T Campbell, Mamie Gao, Andrew W Hahn, Zita Lim, Emily Wang, Jianjun Gao, Amishi Y Shah, Pavlos Msaouel, Nizar M Tannir> ;The Oncologist. 2024 Mar 13
- Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?Mohammad Jad Moussa, Matthew T Campbell, Omar Alhalabi> ;Biomedicines. 2024 Feb 26
- Join now to see all
Journal Articles
- Author Correction: Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated ColitisMatthew T Campbell, Jennifer A Wargo, John R Stroehlein, Padmanee Sharma, Sumit K Subudhi, Gottumukkala S Raju, Jianjun Gao, Alexander J Lazar, Dipen M Maru, Michael T..., Nature
- Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated ColitisJohn R Stroehlein, Sumit K Subudhi, Jennifer A Wargo, Dipen M Maru, Gottumukkala S Raju, Jianjun Gao, Matthew T Campbell, Michael T Tetzlaff, Padmanee Sharma, Nature
- IL-18 Mediates Pro-apoptotic Signaling in Renal Tubular Cells through a Fas Ligand-dependent MechanismZhang, H. Hile, K., Asunuma, H., Vandedrbrink, B., Franke, E., Campbell, MT, Meldrum, KK, American Journal of Physiology- Renal Physiology, 7/1/2011
- Join now to see all
Abstracts/Posters
- Phase I Trial of Sunitinib (S) And Temsirolimus (T) In Metastatic Renal Cell Carcinoma (mRCC)Campbell, MT, Millikan, R., Emre, A.,Xiao, L., Tannir, NM, Genitourinary American Society of Clinical Oncology Meeting, San Francisco, CA, 2/1/2014
- Phase I trial of sunitinib and temsirolus in metastatic renal cell carcinoma.Campbell MT, Millikan R, Emre A, Xiao L, Tannir NM., GU ASCO, San Francisco, 2/2014
- Germline Single Nucleotide Polymorphism (SNP) Predictors of Progression Free Survival and Overall Survival in Advanced Prostate Cancer Patients Treated with Androgen D...Campbell MT, Jung J, Philips S, Mohammadi Y, Carr KA, Davis TL, Li L, Sweeney CJ, Skaar TC, Genitourinary Amercian Society of Clinical Oncology Meeting, Orlando, FL, 2/1/2011
- Join now to see all
Press Mentions
- DFW Healthcare Brief: UTSW Coppell Is Now Open and Medical City Frisco’s AI-Driven Spine Surgery SystemApril 26th, 2023
- UTSW and Children’s Health to Lead Paediatric Cancer Combo Therapy TrialApril 25th, 2023
- MDACC 2018: Debate: What Is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?November 10th, 2018
- Join now to see all
Grant Support
- Young Investigator AwardConquer Cancer Foundation/Kidney Cancer Association2015–2016
- National Institute of Health Loan Repayment AwardNational Institute of Health2014–2016
Professional Memberships
- Member
- Member
- Member
- American Urology AssociationMember
- Society of Urologic OncologyMember
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: